Sterol/Hopanoid Biosynthesis: An Anti-TB Drug Target

甾醇/霍帕尼生物合成:抗结核药物靶点

基本信息

  • 批准号:
    6752797
  • 负责人:
  • 金额:
    $ 24.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-06-15 至 2007-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Multi-drug resistant tuberculosis is increasing in prevalence worldwide; therefore, a greater understanding of the basic biochemistry of Mycobacterium tuberculosis is of utmost importance. Analysis of the M. tuberculosis genome suggests that there may be a biosynthetic pathway analogous to eukaryotic sterol synthesis in this organism. Preliminary evidence indicates that the M. tuberculosis genome encodes enzymes with structural homology to several eukaryotic sterol synthesis enzymes including farnesyl diphosphate synthase, squalene synthase, squalene epoxidase, oxidosqualene cyclase and lanosterol 14a-demethylase. It has been shown that both the M. tuberculosis farnesyl diphosphate synthase and lanosterol 14a-demethylase are functional as well as structural homologs of the eukaryotic enzymes. More importantly, commercial anti-fungal drugs that are known inhibitors of sterol synthesis (specifically oxidosqualene cyclase and lanosterol 14a-demethylase) effectively inhibit the growth of M. tuberculosis in culture. It is hypothesized that M. tuberculosis synthesizes cyclic isoprenoid compounds, perhaps sterols or hopanoids, which are essential to the viability of the organism. Therefore, the specific aims of this proposal are to: 1) identify and characterize cyclic isoprenoid compounds in M. tuberculosis. 2) isolate, enzymatically characterize and determine the essentiality of the sterol synthesis homologs expressed by M. tuberculosis. 3) identify and characterize the active site of the oxidosqualene cyclase homolog. The identification of a sterol/hopanoid biosynthetic pathway in M. tuberculosis and characterization of relevant enzymes represents a novel approach to the identification of previously unsuspected antituberculosis drug targets.
描述(由申请人提供):耐多药结核病是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEAN C CRICK其他文献

DEAN C CRICK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEAN C CRICK', 18)}}的其他基金

Colorado Mycobacteria Conference: Focus on NTM
科罗拉多分枝杆菌会议:聚焦 NTM
  • 批准号:
    10001954
  • 财政年份:
    2021
  • 资助金额:
    $ 24.39万
  • 项目类别:
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs
揭示吡嗪酰胺与其他抗结核药物协同作用的起源
  • 批准号:
    9079347
  • 财政年份:
    2015
  • 资助金额:
    $ 24.39万
  • 项目类别:
Unraveling the Origin of Pyrazinamide's Synergy with other anti-TB Drugs
揭示吡嗪酰胺与其他抗结核药物协同作用的起源
  • 批准号:
    8952987
  • 财政年份:
    2015
  • 资助金额:
    $ 24.39万
  • 项目类别:
HTS assays for the methylerythritol-4-phosphate pathway
4-甲基赤藓糖醇-4-磷酸途径的 HTS 测定
  • 批准号:
    8459369
  • 财政年份:
    2012
  • 资助金额:
    $ 24.39万
  • 项目类别:
HTS assays for the methylerythritol-4-phosphate pathway
4-甲基赤藓糖醇-4-磷酸途径的 HTS 测定
  • 批准号:
    8373656
  • 财政年份:
    2012
  • 资助金额:
    $ 24.39万
  • 项目类别:
HTS assays for the methylerythritol-4-phosphate pathway
4-甲基赤藓糖醇-4-磷酸途径的 HTS 测定
  • 批准号:
    8649013
  • 财政年份:
    2012
  • 资助金额:
    $ 24.39万
  • 项目类别:
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens
类异戊二烯生物合成:A-C 类病原体药物的靶标
  • 批准号:
    7641021
  • 财政年份:
    2008
  • 资助金额:
    $ 24.39万
  • 项目类别:
Isoprenoid Biosynthesis: A Target for Drugs Against Category A-C Pathogens
类异戊二烯生物合成:A-C 类病原体药物的靶标
  • 批准号:
    7126629
  • 财政年份:
    2005
  • 资助金额:
    $ 24.39万
  • 项目类别:
Menaquinone biosynthesis:a drug target in Gram-positive bacteria
甲萘醌生物合成:革兰氏阳性菌的药物靶点
  • 批准号:
    7373343
  • 财政年份:
    2001
  • 资助金额:
    $ 24.39万
  • 项目类别:
Menaquinone biosynthesis:a drug target in Gram-positive bacteria
甲萘醌生物合成:革兰氏阳性菌的药物靶点
  • 批准号:
    7770889
  • 财政年份:
    2001
  • 资助金额:
    $ 24.39万
  • 项目类别:

相似国自然基金

鲜驴乳中游离脂肪酸对Mycobacterium tuberculosis H37Rv活性的影响及机制研究
  • 批准号:
    31760442
  • 批准年份:
    2017
  • 资助金额:
    38.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Fragment to small molecule hit discovery targeting Mycobacterium tuberculosis FtsZ
针对结核分枝杆菌 FtsZ 的小分子片段发现
  • 批准号:
    MR/Z503757/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.39万
  • 项目类别:
    Research Grant
Functional exploration of a deep Mycobacterium tuberculosis phosphoproteome
结核分枝杆菌深层磷酸蛋白质组的功能探索
  • 批准号:
    10656957
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
The role of the gut microbiome in susceptibility to Mycobacterium tuberculosis
肠道微生物组在结核分枝杆菌易感性中的作用
  • 批准号:
    10647554
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
优化结核分枝杆菌多药治疗以实现快速灭菌和耐药性抑制
  • 批准号:
    10567327
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
Analysis of essentiality of thymidylate synthase and methionine adenosyltransferase in Mycobacterium tuberculosis
结核分枝杆菌胸苷酸合酶和甲硫氨酸腺苷转移酶的必要性分析
  • 批准号:
    23K14522
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Structural characterization of MCE transport systems from Mycobacterium tuberculosis
结核分枝杆菌 MCE 转运系统的结构表征
  • 批准号:
    10681871
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
Impact of Mycobacterium tuberculosis on monocyte differentiation in vivo
结核分枝杆菌对体内单核细胞分化的影响
  • 批准号:
    10606380
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
Elucidation of factors affecting environmental persistence of non-tuberculous Mycobacterium tuberculosis and related genomic factors
影响非结核分枝杆菌环境持久性的因素及相关基因组因素的阐明
  • 批准号:
    23H00451
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Structural basis for the induction of dormancy in Mycobacterium tuberculosis
结核分枝杆菌休眠诱导的结构基础
  • 批准号:
    23H02417
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
SIGMA: Small molecule Inhibitors targeting the Genetic determinants of Mutagenesis and Adaptability in Mycobacterium tuberculosis
SIGMA:针对结核分枝杆菌突变和适应性的遗传决定因素的小分子抑制剂
  • 批准号:
    EP/X032817/1
  • 财政年份:
    2023
  • 资助金额:
    $ 24.39万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了